The First mRNA Flu Shot Is Arriving Just in Time for This Winter

Keypoints:

• The FDA approved mFlusiva, Moderna's mRNA flu vaccine, on August 5, 2026
• It's the first mRNA-based flu vaccine ever approved
• In a trial of adults 50 to 64, mFlusiva cut confirmed flu cases by 27% compared to a standard flu shot
• It's fully approved for ages 50 to 64, with accelerated approval for 65 and older pending further data
• The vaccine is expected to reach US retailers in time for the 2026-2027 flu season

The FDA approved mFlusiva on August 5, 2026, Moderna's mRNA-based flu vaccine and the first of its kind ever cleared for use. Unlike traditional flu shots, grown using an inactivated virus in eggs or cells, mFlusiva uses a small piece of genetic code that instructs the body to produce a harmless viral protein, triggering an immune response without ever exposing a person to the actual virus.

The clinical results behind the approval are notably strong for a first-generation product. In a trial of more than 20,000 adults aged 50 to 64, just 411 people who received mFlusiva developed confirmed flu within six months, compared to 557 among a similarly sized group that received a standard-dose flu shot, a 27% reduction in confirmed cases. 

Moderna CEO Stéphane Bancel called the approval reflective of "the ongoing potential of our mRNA platform to help address important public health challenges through continued scientific innovation."

The path here wasn't straightforward. Moderna originally sought approval for a combination flu-and-COVID shot before regulators requested additional standalone data on the flu component, data the company later published in the New England Journal of Medicine. 

Approval for adults 65 and older came through an accelerated pathway instead of full approval, since the FDA wanted it compared against a standard-dose shot even though the CDC already recommends a high-dose vaccine for that age group specifically. 

Moderna says it will track real-world data this winter against the high-dose alternative and submit it to the FDA to help secure full approval for older adults going forward. The vaccine is expected to reach select US retailers in the coming weeks, in time for this year's flu season.